In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback